Boehringer Ingelheim brings development ‘under one roof’ with €230m biologics centre

By Flora Southey

- Last updated on GMT

Getty/Sergey Khakimullin
Getty/Sergey Khakimullin

Related tags: Boehringer ingelheim

Boehringer Ingelheim says Germany-based biologics development facility will support both its research pipeline and contract manufacturing business.

Boehringer Ingelheim has announced plans to invest €230m ($269m) in a Biologics Development Centre (BDC) at its R&D site in Biberach, Germany. The facility – set to launch in 2020 – will house analytical, process development, and manufacturing capabilities for biologics.

According to the Germany-headquartered firm, the site will ‘free up’ capacity for its contract manufacturing business: “In the BDC we will conduct development for biologics from both our research pipeline as well as biopharmaceutical contract manufacturing,” ​spokesperson Matthias Reinig told us.

“As overall development capacity will increase, more resources overall can be dedicated to contract manufacturing development,” ​he added.

The BDC will bring development activities – currently “spread over various places”​ at Biberach – together, Reinig explained: “With the BDC, they will locate under one roof while adding another 100 staff to further extend capacity.”

The investment is the latest in a series of biopharmaceutical facility expansions for Boehringer Ingelheim. In 2017​, the firm broke ground on a €700m mammalian cell culture production plant in Vienna, Austria, and opened​ a contract biomanufacturing plant in Shanghai, China.

In addition, in July 2017,​ the firm announced plans to expand, upgrade, and increase headcount at its biologics manufacturing facility in Fremont, California.

Related news

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars